Briakinumab

What is Briakinumab?

Briakinumab is an investigational human monoclonal antibody designed to target and inhibit the activity of two key cytokines in the immune system: Interleukin-12 (IL-12) and Interleukin-23 (IL-23). These cytokines play crucial roles in inflammatory and autoimmune diseases, such as psoriasis. Developed by Abbott Laboratories (now AbbVie), briakinumab was explored as a potential therapeutic agent for a range of immune-mediated conditions. However, its clinical development was ultimately halted due to emerging safety concerns, leading to its discontinued development before it could receive regulatory approval for market use.

How Does it Work?

The mechanism of action of briakinumab centers on its ability to bind to the p40 protein subunit, which is common to both IL-12 and IL-23. By binding to this subunit, briakinumab effectively prevents IL-12 and IL-23 from interacting with their respective receptors on immune cells. This blockade disrupts the signaling pathways that these cytokines normally initiate, thereby dampening the inflammatory response. In conditions like psoriasis, the overactivity of the IL-12/IL-23 pathway contributes to the proliferation of skin cells and the characteristic inflammation. By inhibiting this pathway, briakinumab aimed to reduce inflammation and alleviate symptoms. Its action is similar to other biologic drugs that target this pathway, such as ustekinumab, which has been successfully approved for use in psoriasis and psoriatic arthritis.

Medical Uses

Briakinumab was primarily investigated for the treatment of moderate to severe chronic plaque psoriasis. Clinical trials demonstrated its efficacy in significantly reducing the severity and extent of psoriatic lesions in many patients. Beyond psoriasis, researchers also explored briakinumab's potential in other autoimmune conditions, including psoriatic arthritis and Crohn's disease, given the shared inflammatory pathways involving IL-12 and IL-23. Despite showing promise in terms of efficacy, the development program was terminated. The primary reason for this decision was the identification of an increased risk of serious infections and major adverse cardiovascular events (MACE) in patients receiving briakinumab compared to placebo or other treatments, raising significant safety concerns that outweighed its potential benefits.

Dosage

As briakinumab never received regulatory approval and its development was discontinued, there is no standardized or approved dosage regimen for clinical use. During its investigational phases, briakinumab was typically administered via subcutaneous injection. Clinical trials evaluated various dosing schedules and concentrations to determine optimal efficacy and safety. For instance, studies for psoriasis often involved initial loading doses followed by maintenance doses administered at regular intervals, such as every four or eight weeks. However, it is crucial to reiterate that these dosages were part of research protocols and are not applicable for patient treatment, as the drug is not available on the market.

Side Effects

The side effect profile of briakinumab was a critical factor in its discontinuation. Common adverse events observed in clinical trials included injection site reactions (e.g., pain, redness, swelling) and upper respiratory tract infections. More concerningly, briakinumab was associated with a higher incidence of serious adverse events. Patients treated with briakinumab experienced an elevated risk of serious infections, including bacterial, fungal, and viral infections, some requiring hospitalization. There was also an increased risk of malignancies, though the direct causal link was still under investigation. A significant safety signal was the increased incidence of major adverse cardiovascular events (MACE), which encompassed heart attack, stroke, and cardiovascular death. These safety concerns ultimately led to the decision to halt the drug's development.

Drug Interactions

Due to its immunosuppressive mechanism, briakinumab had the potential for interactions with other medications, particularly those that also suppress the immune system. Co-administration with other immunosuppressants, such as methotrexate or cyclosporine, could theoretically increase the risk of serious infections. The use of live vaccines was generally contraindicated during treatment with briakinumab, as the attenuated viruses in these vaccines could potentially cause infection in an immunocompromised individual. However, because briakinumab's development was discontinued, comprehensive drug interaction studies beyond the initial clinical trials were not fully completed, and precise guidelines for interactions were never established for clinical practice.

FAQ

• Is Briakinumab approved for medical use? No, briakinumab's development was discontinued, and it never received regulatory approval for any medical condition.
• What conditions was Briakinumab intended to treat? It was primarily investigated for moderate to severe plaque psoriasis, and also explored for psoriatic arthritis and Crohn's disease.
• Why was Briakinumab's development stopped? Development was halted due to significant safety concerns, including an increased risk of serious infections and major adverse cardiovascular events (MACE).
• How does Briakinumab compare to other psoriasis treatments? Briakinumab targeted the same IL-12/IL-23 pathway as approved drugs like ustekinumab. While it showed efficacy, its safety profile was deemed unfavorable compared to available alternatives.
• Are there alternatives to Briakinumab for psoriasis? Yes, several approved biologic treatments target similar pathways, including ustekinumab (an IL-12/IL-23 inhibitor) and other IL-23 specific inhibitors like risankizumab, guselkumab, and tildrakizumab, which have more favorable safety profiles.

Products containing Briakinumab are available through trusted online pharmacies. You can browse Briakinumab-based medications at ShipperVIP or Medicenter.

Summary

Briakinumab was an investigational human monoclonal antibody that showed promise as an IL-12/IL-23 inhibitor for the treatment of moderate to severe psoriasis and other autoimmune diseases. Its mechanism involved blocking key inflammatory cytokines, leading to reduced disease activity in clinical trials. However, the drug's development was ultimately marked by its discontinued development due to significant safety concerns, including an increased incidence of serious infections and major adverse cardiovascular events. While briakinumab demonstrated efficacy, its unfavorable risk-benefit profile prevented it from reaching the market. Its story highlights the rigorous safety standards in pharmaceutical development and paved the way for the development of safer and more effective IL-12/IL-23 inhibitors currently available for patients with chronic inflammatory conditions.